LifeArc

LifeArc Ventures - six new investments, portfolio progress and an expanding investment team

Retrieved on: 
Thursday, January 25, 2024

LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.

Key Points: 
  • LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.
  • We have expanded our investment team, adding two new members and further strengthened our Early Ventures Investment Committee through the appointment of a new Chair and new independent member.
  • Jon joined us from M Ventures' biotechnology investment team and previously was an associate within the healthcare investment banking team at UBS, after starting his career as a doctor.
  • In addition, Clare Terlouw, Head of LifeArc Ventures, was re-elected to the BioIndustry Association (BIA) Board of Directors for the third time.

LifeArc Ventures - six new investments, portfolio progress and an expanding investment team

Retrieved on: 
Thursday, January 25, 2024

LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.

Key Points: 
  • LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.
  • We have expanded our investment team, adding two new members and further strengthened our Early Ventures Investment Committee through the appointment of a new Chair and new independent member.
  • Jon joined us from M Ventures' biotechnology investment team and previously was an associate within the healthcare investment banking team at UBS, after starting his career as a doctor.
  • In addition, Clare Terlouw, Head of LifeArc Ventures, was re-elected to the BioIndustry Association (BIA) Board of Directors for the third time.

Conduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business Combination

Retrieved on: 
Friday, September 22, 2023

SAN DIEGO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Limited (“Conduit Pharmaceuticals”), a multi-asset clinical-stage disease-agnostic life science company providing an efficient model for compound development, and Murphy Canyon Acquisition Corp., a special purpose acquisition company (Nasdaq: MURF) (“MURF”), announced today the completion of the previously announced business combination (the “Transaction”).

Key Points: 
  • SAN DIEGO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Limited (“Conduit Pharmaceuticals”), a multi-asset clinical-stage disease-agnostic life science company providing an efficient model for compound development, and Murphy Canyon Acquisition Corp., a special purpose acquisition company (Nasdaq: MURF) (“MURF”), announced today the completion of the previously announced business combination (the “Transaction”).
  • Existing Conduit Pharmaceuticals shareholders will own approximately 90% of the combined company’s common stock issued and outstanding as of the closing.
  • The warrants have an exercise price of $11.50, are exercisable after 30 days after the completion of the business combination and expire five years after the completion of the Transaction.
  • The Transaction was completed on September 22, 2023
    In connection with the completion of the Transaction, MURF changed its name to Conduit Pharmaceuticals Inc.

New NEURii Research Collaboration Between Eisai, Gates Ventures, Health Data Research UK, Lifearc and The University of Edinburgh to Develop Digital Solutions for Dementia is Announced

Retrieved on: 
Friday, June 30, 2023

- NEURii collaboration builds on Eisai's extensive experience in delivering innovative treatments in neurology and supports ongoing contributions to the global digital health ecosystem.

Key Points: 
  • - NEURii collaboration builds on Eisai's extensive experience in delivering innovative treatments in neurology and supports ongoing contributions to the global digital health ecosystem.
  • TOKYO, HATFIELD, SEATTLE, LONDON, and EDINBURGH, June 30, 2023 - (JCN Newswire) - Eisai, Gates Ventures, Health Data Research UK (HDR UK), LifeArc and The University of Edinburgh announced today a new two-year collaborative research agreement.
  • NEURii will focus its initial efforts to develop data and digital solutions to complement approved treatment options for patients and solve issues related to the prediction, prevention, management, and treatment of dementia related disorders.
  • It is envisaged that NEURii partners will explore further opportunities to scale up the program developing digital health solutions worldwide.

Groundbreaking new £100m LifeArc programme aims to improve the lives of people living with a rare disease

Retrieved on: 
Thursday, July 6, 2023

Self-funded medical research organisation and charity, LifeArc, to launch a groundbreaking Rare Disease Translational Challenge that will invest more than £100m by 2030 to improve the lives of people living with a rare disease.

Key Points: 
  • Self-funded medical research organisation and charity, LifeArc, to launch a groundbreaking Rare Disease Translational Challenge that will invest more than £100m by 2030 to improve the lives of people living with a rare disease.
  • The first commitment will be £40m for the creation of up to five Translational Rare Disease Centres across the UK that will specialise in different aspects of rare disease research.
  • The Rare Disease Translational Challenge will be a game-changer for people living with a rare disease.”
    Catriona Crombie, Head of Rare Disease Translational Challenge at Life Arc, said: “Through our Rare Disease Translational Challenge, we will leverage our expertise in drug discovery, diagnostics, and translational science.
  • In the 2023 England Rare Diseases Action Plan we highlighted our ongoing commitment to investment in rare disease research through the NIHR MRC Rare Disease Research Platform and renewed investment in the NIHR Biomedical Research Centres.

LifeArc Ventures - strong performance in 2022 & sustained investment in innovation

Retrieved on: 
Wednesday, February 1, 2023

LONDON, Feb. 1, 2023 /PRNewswire/ -- LifeArc Ventures, which is committed to investing in innovative early-stage life science companies, today provides an update on its portfolio.

Key Points: 
  • "We pride ourselves on the hands-on support we give our portfolio companies, offering strategic, practical and scientific guidance as well as funding.
  • We believe the award for LifeArc recognises the unique combination of skills and expertise that LifeArc and LifeArc Ventures provide to support and promote life changing science.
  • You can now follow us on our dedicated LinkedIn page and Twitter, and on our upcoming new LifeArc Ventures website.
  • We're open to new opportunities and welcome introductions, so please get in touch if you think we can help.

LifeArc Ventures - strong performance in 2022 & sustained investment in innovation

Retrieved on: 
Wednesday, February 1, 2023

LONDON, Feb. 1, 2023 /PRNewswire/ -- LifeArc Ventures, which is committed to investing in innovative early-stage life science companies, today provides an update on its portfolio.

Key Points: 
  • "We pride ourselves on the hands-on support we give our portfolio companies, offering strategic, practical and scientific guidance as well as funding.
  • We believe the award for LifeArc recognises the unique combination of skills and expertise that LifeArc and LifeArc Ventures provide to support and promote life changing science.
  • You can now follow us on our dedicated LinkedIn page and Twitter, and on our upcoming new LifeArc Ventures website.
  • We're open to new opportunities and welcome introductions, so please get in touch if you think we can help.

LifeArc Ventures invests in Surgery Hero, world's first digital coaching clinic for patients

Retrieved on: 
Tuesday, November 15, 2022

Headquartered in London, Surgery Hero is a digital clinic that helps people prepare for and recover from surgery at home.

Key Points: 
  • Headquartered in London, Surgery Hero is a digital clinic that helps people prepare for and recover from surgery at home.
  • In addition to LifeArc Ventures, the latest round of funding welcomes new investors Crista Galli Ventures and Clarendon Fund Managers, with pre-seed investors SFC Capital following on.
  • Damien Lane (founding partner of Episode 1 Ventures) and Imran Hamid (former surgeon and Senior Investment Principal at LifeArc Ventures) both join the board.
  • "Surgery Hero has the potential to significantly improve clinical outcomes and experience for patients undergoing surgery," said Dr Imran Hamid, Senior Investment Principal at LifeArc Ventures.

LifeArc Ventures invests in Surgery Hero, world's first digital coaching clinic for patients

Retrieved on: 
Tuesday, November 15, 2022

Headquartered in London, Surgery Hero is a digital clinic that helps people prepare for and recover from surgery at home.

Key Points: 
  • Headquartered in London, Surgery Hero is a digital clinic that helps people prepare for and recover from surgery at home.
  • In addition to LifeArc Ventures, the latest round of funding welcomes new investors Crista Galli Ventures and Clarendon Fund Managers, with pre-seed investors SFC Capital following on.
  • Damien Lane (founding partner of Episode 1 Ventures) and Imran Hamid (former surgeon and Senior Investment Principal at LifeArc Ventures) both join the board.
  • "Surgery Hero has the potential to significantly improve clinical outcomes and experience for patients undergoing surgery," said Dr Imran Hamid, Senior Investment Principal at LifeArc Ventures.

World-Class Forum for Life Science Innovation CNS Summit Taps Cumulus Neuroscience to Share New Data

Retrieved on: 
Thursday, November 10, 2022

"At the heart of scientific innovation is collaboration and knowledge sharing," said Dr. Bhatti. "The CNS Summit gathers the life sciences community united around a shared goal -- to accelerate innovation and improve patient experience and outcomes. We are honored to not only attend alongside and learn from these leaders but to present our own vital research and discuss the future of research, diagnosis and treatment for neuropsychological conditions."

Key Points: 
  • "At the heart of scientific innovation is collaboration and knowledge sharing," said Dr. Bhatti.
  • "The CNS Summit gathers the life sciences community united around a shared goal -- to accelerate innovation and improve patient experience and outcomes.
  • The CNS Summit takes place from November 17-20 in Boca Raton, Florida, and brings together leading pharma and biotech executives dedicated to innovating care in the life sciences.
  • Cumulus Neuroscience is a leader in advancing clinical trial data, creating tools for its partners to harness data, and transforming and accelerating diagnosis and care for patients with central nervous system disorders.